THANK YOU FOR JOINING US AT
2023 AMP Annual Meeting
November 14-18 | Salt Lake City, UT
Closing the precision oncology gap
We create clarity for patients and their clinicians by removing barriers to precision oncology testing
in order to make timely, personalized cancer treatments a reality for all.
Democratizing access to CGP
with distributed kits
Delivering rapid insights to guide
personalized treatment decisions
Elevating the standard
of cancer care for all
View our posters
Friday, November 17, 2023
9:15 a.m. – 10:15 a.m. Mountain Time
#G004 - A Consensus-Based Machine Learning Framework to Determine Genetically Inferred Ancestry (GIA) from Comprehensive Genomic Profiling (CGP) Sequencing Results
View poster
#ST038 - Tumor Diagnosis Re-Classification Based on Comprehensive Molecular Profiling Results Helps Guide Precision Medicine Strategy for Cancer Patients (PATHGROUP)
#ST080 - Laboratory Automation of PGDx elio™ Tissue Complete on the Biomek NGeniuS System Enables Accurate and Reproducible Comprehensive Genomic Profiling
View poster
Saturday, November 18, 2023
9:15 a.m. – 10:15 a.m. Mountain Time
#ST007 - Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response
View poster
#ST011 - LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma
View poster
#ST075 - Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making
View poster
#ST077 - Real-World Evidence Demonstrating the Clinical Performance and Utility of the Labcorp® Plasma Focus™ Liquid Biopsy Test
View poster
#ST079 - Analytical Validation of PGDx elio™ Plasma Focus Dx to Facilitate Precision Oncology Through Decentralized Liquid Biopsy for Solid Tumor Profiling
View poster
#ST087 - Performance Assessment of the Labcorp® Plasma Complete™ Test for Comprehensive Genomic Profiling of Solid Tumors Through Liquid Biopsy
View poster
#ST125 - Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy
View poster
#ST135 - Detecting Molecular Residual Disease Through Integrated Tumor Tissue, Germline, and Plasma Whole Genome Sequencing Analyses
View poster
#ST141 - Genomic stability of prostate cancers with homologous recombination gene alterations
View poster
#ST143 - Comparative Analysis of Chromosomal Microarray (CMA) and 505-gene Next-Generation Sequencing (NGS) Panel for Homologous Recombination Deficiency (HRD) Phenotype Assessment in Solid Tumors (AUGUSTA)
Get Email Updates
Stay current by signing up to receive the latest news and updates on tests and services.